Caris Life Sciences, Inc. (CAI): Capital Expenditures
$16.26M
Year ended 2025-12-31
$44.60M
Trailing 12 months to 2026-06-30
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.26M | +92.6% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $8.44M | -62.2% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $22.32M | n/a | 2026-03-03, From 2023-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $16.26M | +92.6% |
| Guardant Health, Inc. (GH) | 2025-12-31 | $48.31M | +37.7% |
| Veracyte, Inc. (VCYT) | 2025-12-31 | $9.68M | -14.3% |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | $36.02M | +27.2% |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | $22.57M | -44.0% |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $8.88M | +64.4% |
| Natera, Inc. (NTRA) | 2025-12-31 | $106.19M | +59.9% |
| Fortrea Holdings Inc. (FTRE) | 2025-12-31 | $25.20M | -1.2% |
| GRAIL, Inc. (GRAL) | 2025-12-31 | $909.0K | -82.5% |
Compare CAI, GH, VCYT, CSTL side by side · Screen every company in Services-Medical Laboratories ↗